Progress in the Formulation and Delivery of Somatostatin Analogues for Acromegaly

Files in This Item:
File Description SizeFormat 
Fattah_&_Brayden_Ther_Del_RMS.pdf924.74 kBAdobe PDFDownload
Title: Progress in the Formulation and Delivery of Somatostatin Analogues for Acromegaly
Authors: Fattah, SarinjBrayden, David James
Permanent link:
Date: 25-Sep-2017
Online since: 2018-03-25T01:00:40Z
Abstract: A 14-amino acid cystin bridge-containing neuropeptide was discovered in 1973 and designated as "growth hormone-inhibiting hormone (GHIH)," i.e. somatostatin. Its discovery led to the synthesis of three analogues which were licenced for the treatment of acromegaly: octreotide, lanreotide, and pasireotide. Somatostatin analogues are currently approved only as either subcutaneous (s.c.) or intramuscular (i.m.) long-acting injections. We examine the challenges that must be overcome to create oral formulations of somatostatin analogues and examine selected clinical trial data. While octreotide has low intestinal permeability, similar to almost all other peptides, it has an advantage of being more stable against intestinal peptidases. The development of new oral formulation strategies may eventually allow for the successful oral administration of potent somatostatin analogues with high therapeutic indices.
Funding Details: European Commission Horizon 2020
Science Foundation Ireland
Type of material: Journal Article
Publisher: Future Science
Journal: Therapeutic delivery
Volume: 8
Issue: 10
Start page: 867
End page: 878
Copyright (published version): 2017 Future Science
Keywords: SomatostatinOctreotideOral peptide deliveryIntestinal permeabilityAcromegaly
DOI: 10.4155/tde-2017-0064
Language: en
Status of Item: Peer reviewed
Appears in Collections:Conway Institute Research Collection
SBI Research Collection
Veterinary Medicine Research Collection

Show full item record

Citations 50

Last Week
Last month
checked on Jul 18, 2019

Google ScholarTM



This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.